Pawanjit Sarna, MD
Pulmonary Disease · South Boston, VANPI 1457379422
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Intuitive Surgical at 53.6% of the total. Reporting peaked in 2023 at $12,378 and has fallen 84.2% since, to $1,961 in 2025.
Across 486 payments — averaging $39.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- GSK$2K
- AstraZeneca$2K
- Mallinckrodt Hospital Products Inc.$630
- Boehringer Ingelheim$622
- Regeneron Healthcare Solutions, Inc.$487
- plus $4K from 34 others
What the payments were for
- Travel & lodging$1,0556%
- Food & beverage$8,69346%
- Education$9,22149%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $10,165 |
| GSK | 140 | $1,821 |
| AstraZeneca | 61 | $1,679 |
| Mallinckrodt Hospital Products Inc. | 27 | $630 |
| Boehringer Ingelheim | 34 | $622 |
| Regeneron Healthcare Solutions, Inc. | 27 | $487 |
| Insmed, Inc. | 22 | $405 |
| Mylan Specialty L.p. | 21 | $312 |
| Sanofi | 17 | $294 |
| Grifols USA, LLC | 14 | $290 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $274 |
| Philips North America LLC | 10 | $170 |
| Amgen | 8 | $165 |
| Bayer | 4 | $160 |
| ANI Pharmaceuticals, Inc. | 5 | $148 |
| Genentech USA, Inc. | 11 | $125 |
| Actelion Pharmaceuticals US, Inc. | 7 | $122 |
| Verona Pharma, Inc. | 5 | $110 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Vifor Pharma, Inc. | 4 | $88 |
| Viatris Specialty LLC | 4 | $79 |
| Baxter Healthcare | 3 | $76 |
| Paratek Pharmaceuticals, Inc. | 4 | $68 |
| Merck | 4 | $67 |
| Pharming Healthcare, Inc. | 4 | $66 |
| Novartis | 4 | $57 |
| United Therapeutics Corporation | 3 | $49 |
| Pulmonx Corporation | 2 | $47 |
| Inogen, Inc. | 2 | $39 |
| Electromed, Inc. | 3 | $36 |
| Atricure, Inc. | 1 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Circassia Inc. | 2 | $24 |
| Phadia US Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Pfizer | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,969 in reported general payments places this provider in the 85th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 364 | $322,701 |
| OfevNintedanib Esylate | 20 | $273,338 |
| Dupixent PenDupilumab | 12 | $47,320 |
| Spiriva RespimatTiotropium Bromide | 61 | $42,306 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 49 | $34,345 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $33,176 |
| SymbicortBudesonide/Formoterol Fumarate | 86 | $26,858 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $19,740 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $12,378 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 56 | $10,221 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 321 | $8,195 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $5,945 |
| BreynaBudesonide/Formoterol Fumarate | 24 | $4,233 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $4,209 |
| Arnuity ElliptaFluticasone Furoate | 20 | $3,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,821 | $364,742467 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $622 | $349,989130 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,679 | $60,035138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in South Boston
- Terrance TruittSouth Boston$108K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
- Ellen VolkerCharlottesville$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.